10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Adam Keeney has been appointed president and chief executive of NodThera, a biotech focused on the discovery and development of NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. 24 September 2018
A High Court case win by 12 National Health Service (NHS) Clinical Commissioning Groups (CCGs) in favor of prescribing the significantly cheaper anti-vascular endothelial growth factor (anti-VEGF), Avastin (bevacizumab), over Novartis’ (NOVN: VX) and Bayer’s (BAYN: DE) licensed anti-VEGF eye drugs has import implications, says analyst. 24 September 2018
US biotech Amarin today announced positive top-line results from the Vascepa (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT, a global study of 8,179 statin-treated adults with elevated CV risk. 24 September 2018
With CAR-T therapies closer than ever to delivering on their promise but still facing significant obstacles, Eva Marchese and Cécile Matthews from Charles River Associates provide an Expert View on the topic. 24 September 2018
After raising a bumper $96 million through its Nasdaq listing last week, Y-mAbs Therapeutics continued to gain value in its first day of trading, rising 50% to $24 per share. 24 September 2018
Swiss pharma giant Novartis on Sunday announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6mg versus aflibercept over four visits between weeks 36 to 48. Retinal fluid is a key marker of disease activity in neovascular age-related macular degeneration (nAMD). 24 September 2018
When Novartis’ Kymriah (tisagenlecleucel) was made available to a small group of young patients in an agreement with NHS England less than a month ago, the decision came just 10 days after the drug was approved in Europe. 23 September 2018
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its September 2018 meeting recommended 13 medicines for approval, including three orphan medicines, with the latter being the following. 21 September 2018
San Franciscan microbial genomics specialist uBiome has raised $83 million in a series C financing round directed at funding an expansion into therapeutics. 21 September 2018
South Korean drugmaker Celltrion has signed an ‘incubation’ agreement with Emory University in Atlanta, USA, to support the research and development of new drug candidates for atherosclerosis. 20 September 2018
A few short months after Merck & Co won its first Chinese approval for flagship immuno-oncology product Keytruda (pembrolizumab), the firm has reportedly agreed a price reduction plan that will enable patients to gain access for around half the US list price. 20 September 2018
Following US approval last month, soon-to-be Takeda Pharmaceutical acquisition Shire has now also been granted authorization in Canada for Takhzyro (lanadelumab), as a treatment for hereditary angioedema (HAE). 20 September 2018
A possible $1 billion initial public offering on the Hong Kong Stock Exchange could give the lie to rumors that the spate of bullish biotech listings in China is about to end. 20 September 2018
Although Novartis’ CAR-T therapy Kymriah (tisagenlecleucel-T) was accepted onto the UK’s Cancer Drugs Fund (CDF) for children with a type of leukemia, adults with diffuse large B-cell lymphoma (DLBCL) have not yet been afforded the same treatment. 19 September 2018
Two tech clusters in Paris are lending their support to the Hu-PreciMED project (Human Precision MEDicine), designed to bolster the precision medicine industry in France. 19 September 2018
Having only in July announced an agreement with an unnamed US biopharma company for its hRPC retinal stem cell technology and therapeutic programs, shares of UK cell-based therapies company ReNeuron plunged nearly 20% to 65.00 pence by early afternoon today, when it revealed that the American firm has pulled out of the deal. 19 September 2018
US biotech firm Viking Therapeutics shares rocketed 140% in pre-market trading on Tuesday, hitting an all time high of $24, after the company reported positive results in a mid-stage trial of a treatment for non-alcoholic fatty liver disease (NAFLD). 19 September 2018
Netherlands-based Pharming Group saw its share plunge 29.05% to 0.69 euros by mid-morning today, after it revealed a further setback in its attempt to widen the use of its leading drug. 19 September 2018
Japanese drugmaker Ono Pharmaceutical and US biotech Fate Therapeutics have signed a deal to develop and commercialize two off-the-shelf CAR-T therapies for cancer. 18 September 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024